Form 4: Sarepta Therapeutics Executive Louise Rodino-Klapac Reports Stock Transaction

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Summary

• On March 4, 2025, Louise Rodino-Klapac, Head of R&D and CSO of Sarepta Therapeutics, Inc. (SRPT), reported a transaction involving the disposition of 1,704 shares of common stock.
• The shares were sold at a price of $101.34 per share to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 3, 2021.
• Following the transaction, Rodino-Klapac directly owns 65,322 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to tax obligations, so it doesn't necessarily indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's stock. This filing provides transparency into the transactions of company insiders, allowing investors to see if those with inside knowledge of the company are buying or selling shares.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates